File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus
  • Basic View
  • Metadata View
  • XML View
TitleAbnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus
 
AuthorsSun, LY1
Zhou, KX1
Feng, XB1
Zhang, HY1
Ding, XQ1
Jin, O2
Lu, LW2
Lau, CS2
Hou, YY1
Fan, LM3
 
KeywordsBone morrow CD34+ cells
CD166
Systemic lupus erythematosus
 
Issue Date2007
 
PublisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/
 
CitationClinical Rheumatology, 2007, v. 26 n. 12, p. 2073-2079 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10067-007-0621-2
 
AbstractDefects of hematopoietic stem cells (HSCs) have been suggested to contribute to the development of systemic lupus erythematosus (SLE). The aim of this study was to investigate the phenotypic characteristics of bone marrow (BM) CD34+ cells in patients with SLE and its relationship with SLE disease activity. Ten SLE patients and 10 healthy subjects were recruited and their BM CD34+ cells were analyzed by flow cytometric analysis with CD45/SSC gating for the expression of CD90, CD95, CD117, CD123, CD164, CD166, FAS-L, and HLA-DR. The percentage of BM CD34+ cells was significantly decreased in active SLE patients (1.48 ± 0.41%, n=7) compared to the healthy controls (2.31 ± 0.75%, n=10, p<0.01), but no significant difference was found between the inactive patients (2.04 ± 0.44%, n=3) and the controls. The expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in SLE patients (48.31 ± 10.59%, 44.9 ± 21.5%, 30.9 ± 19.54%, respectively, n=10) when compared with the control subjects (24.33 ± 11.1%, 19.5 ± 4.4%, 10.7 ± 5.5%, respectively, n=10, p<0.05). The increased CD123 expression was negatively correlated with the number of peripheral white blood cells (r=-0.700, p<0.05, n=10). The percentage of CD166 expression was found significantly correlated with the index of SLE disease activity (r=0.472, p<0.05, n=10) and 24 h proteinuria (r=0.558, p<0.05, n=10), but negatively correlated with serum C3 level (r=-0.712, p<0.01, n=10). Our study found that the surface marker expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in patients. This supports the hypothesis that there are abnormalities of the HSC in SLE. Since CD166 and CD123 correlated with the overall lupus activity, their role as a biomarker of inflammatory disease activity also requires further study. © Clinical Rheumatology 2007.
 
ISSN0770-3198
2012 Impact Factor: 2.037
2012 SCImago Journal Rankings: 0.674
 
DOIhttp://dx.doi.org/10.1007/s10067-007-0621-2
 
ISI Accession Number IDWOS:000250833300010
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSun, LY
 
dc.contributor.authorZhou, KX
 
dc.contributor.authorFeng, XB
 
dc.contributor.authorZhang, HY
 
dc.contributor.authorDing, XQ
 
dc.contributor.authorJin, O
 
dc.contributor.authorLu, LW
 
dc.contributor.authorLau, CS
 
dc.contributor.authorHou, YY
 
dc.contributor.authorFan, LM
 
dc.date.accessioned2010-09-06T09:47:46Z
 
dc.date.available2010-09-06T09:47:46Z
 
dc.date.issued2007
 
dc.description.abstractDefects of hematopoietic stem cells (HSCs) have been suggested to contribute to the development of systemic lupus erythematosus (SLE). The aim of this study was to investigate the phenotypic characteristics of bone marrow (BM) CD34+ cells in patients with SLE and its relationship with SLE disease activity. Ten SLE patients and 10 healthy subjects were recruited and their BM CD34+ cells were analyzed by flow cytometric analysis with CD45/SSC gating for the expression of CD90, CD95, CD117, CD123, CD164, CD166, FAS-L, and HLA-DR. The percentage of BM CD34+ cells was significantly decreased in active SLE patients (1.48 ± 0.41%, n=7) compared to the healthy controls (2.31 ± 0.75%, n=10, p<0.01), but no significant difference was found between the inactive patients (2.04 ± 0.44%, n=3) and the controls. The expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in SLE patients (48.31 ± 10.59%, 44.9 ± 21.5%, 30.9 ± 19.54%, respectively, n=10) when compared with the control subjects (24.33 ± 11.1%, 19.5 ± 4.4%, 10.7 ± 5.5%, respectively, n=10, p<0.05). The increased CD123 expression was negatively correlated with the number of peripheral white blood cells (r=-0.700, p<0.05, n=10). The percentage of CD166 expression was found significantly correlated with the index of SLE disease activity (r=0.472, p<0.05, n=10) and 24 h proteinuria (r=0.558, p<0.05, n=10), but negatively correlated with serum C3 level (r=-0.712, p<0.01, n=10). Our study found that the surface marker expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in patients. This supports the hypothesis that there are abnormalities of the HSC in SLE. Since CD166 and CD123 correlated with the overall lupus activity, their role as a biomarker of inflammatory disease activity also requires further study. © Clinical Rheumatology 2007.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationClinical Rheumatology, 2007, v. 26 n. 12, p. 2073-2079 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10067-007-0621-2
 
dc.identifier.doihttp://dx.doi.org/10.1007/s10067-007-0621-2
 
dc.identifier.epage2079
 
dc.identifier.hkuros132284
 
dc.identifier.isiWOS:000250833300010
 
dc.identifier.issn0770-3198
2012 Impact Factor: 2.037
2012 SCImago Journal Rankings: 0.674
 
dc.identifier.issue12
 
dc.identifier.openurl
 
dc.identifier.pmid17447103
 
dc.identifier.scopuseid_2-s2.0-36248958730
 
dc.identifier.spage2073
 
dc.identifier.urihttp://hdl.handle.net/10722/88771
 
dc.identifier.volume26
 
dc.languageeng
 
dc.publisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofClinical Rheumatology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subject.meshAntigens, CD - biosynthesis
 
dc.subject.meshAntigens, CD34 - biosynthesis
 
dc.subject.meshBone Marrow Cells - immunology - metabolism
 
dc.subject.meshCell Adhesion Molecules, Neuronal - biosynthesis
 
dc.subject.meshLupus Erythematosus, Systemic - immunology - metabolism - pathology
 
dc.subjectBone morrow CD34+ cells
 
dc.subjectCD166
 
dc.subjectSystemic lupus erythematosus
 
dc.titleAbnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Sun, LY</contributor.author>
<contributor.author>Zhou, KX</contributor.author>
<contributor.author>Feng, XB</contributor.author>
<contributor.author>Zhang, HY</contributor.author>
<contributor.author>Ding, XQ</contributor.author>
<contributor.author>Jin, O</contributor.author>
<contributor.author>Lu, LW</contributor.author>
<contributor.author>Lau, CS</contributor.author>
<contributor.author>Hou, YY</contributor.author>
<contributor.author>Fan, LM</contributor.author>
<date.accessioned>2010-09-06T09:47:46Z</date.accessioned>
<date.available>2010-09-06T09:47:46Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Clinical Rheumatology, 2007, v. 26 n. 12, p. 2073-2079</identifier.citation>
<identifier.issn>0770-3198</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/88771</identifier.uri>
<description.abstract>Defects of hematopoietic stem cells (HSCs) have been suggested to contribute to the development of systemic lupus erythematosus (SLE). The aim of this study was to investigate the phenotypic characteristics of bone marrow (BM) CD34+ cells in patients with SLE and its relationship with SLE disease activity. Ten SLE patients and 10 healthy subjects were recruited and their BM CD34+ cells were analyzed by flow cytometric analysis with CD45/SSC gating for the expression of CD90, CD95, CD117, CD123, CD164, CD166, FAS-L, and HLA-DR. The percentage of BM CD34+ cells was significantly decreased in active SLE patients (1.48 &#177; 0.41%, n=7) compared to the healthy controls (2.31 &#177; 0.75%, n=10, p&lt;0.01), but no significant difference was found between the inactive patients (2.04 &#177; 0.44%, n=3) and the controls. The expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in SLE patients (48.31 &#177; 10.59%, 44.9 &#177; 21.5%, 30.9 &#177; 19.54%, respectively, n=10) when compared with the control subjects (24.33 &#177; 11.1%, 19.5 &#177; 4.4%, 10.7 &#177; 5.5%, respectively, n=10, p&lt;0.05). The increased CD123 expression was negatively correlated with the number of peripheral white blood cells (r=-0.700, p&lt;0.05, n=10). The percentage of CD166 expression was found significantly correlated with the index of SLE disease activity (r=0.472, p&lt;0.05, n=10) and 24 h proteinuria (r=0.558, p&lt;0.05, n=10), but negatively correlated with serum C3 level (r=-0.712, p&lt;0.01, n=10). Our study found that the surface marker expression of CD95, CD123, and CD166 on BM CD34+ cells were significantly increased in patients. This supports the hypothesis that there are abnormalities of the HSC in SLE. Since CD166 and CD123 correlated with the overall lupus activity, their role as a biomarker of inflammatory disease activity also requires further study. &#169; Clinical Rheumatology 2007.</description.abstract>
<language>eng</language>
<publisher>Springer-Verlag London Ltd. The Journal&apos;s web site is located at http://link.springer.de/link/service/journals/10067/</publisher>
<relation.ispartof>Clinical Rheumatology</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Bone morrow CD34+ cells</subject>
<subject>CD166</subject>
<subject>Systemic lupus erythematosus</subject>
<subject.mesh>Antigens, CD - biosynthesis</subject.mesh>
<subject.mesh>Antigens, CD34 - biosynthesis</subject.mesh>
<subject.mesh>Bone Marrow Cells - immunology - metabolism</subject.mesh>
<subject.mesh>Cell Adhesion Molecules, Neuronal - biosynthesis</subject.mesh>
<subject.mesh>Lupus Erythematosus, Systemic - immunology - metabolism - pathology</subject.mesh>
<title>Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0770-3198&amp;volume=26&amp;issue=12&amp;spage=2073&amp;epage=2079&amp;date=2007&amp;atitle=Abnormal+surface+markers+expression+on+bone+marrow+CD34++cells+and+correlation+with+disease+activity+in+patients+with+systemic+lupus+erythematosus</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s10067-007-0621-2</identifier.doi>
<identifier.pmid>17447103</identifier.pmid>
<identifier.scopus>eid_2-s2.0-36248958730</identifier.scopus>
<identifier.hkuros>132284</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-36248958730&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>26</identifier.volume>
<identifier.issue>12</identifier.issue>
<identifier.spage>2073</identifier.spage>
<identifier.epage>2079</identifier.epage>
<identifier.isi>WOS:000250833300010</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Nanjing University, School of Medicine
  2. The University of Hong Kong
  3. Nanjing Medical University